Cancer patients can respond very differently to the same treatment, while current testing may not reliably identify the therapy most likely to work for each tumor.
R&D Focus
Genomics and multi-omics for patient stratification and treatment selection
Innovative Solution
SageMedic develops a genome-free SAGE Direct Platform that introduces the next generation of precision medicine by directly testing effective cancer treatments on a live tissue biopsy of a patient.
Investment Funding
Last Funding Stage
Series A
Last Funding Date
29-12-2021
Startup Stage
Early Stage
Lead Investors
Keiretsu Capital, Keiretsu Forum Northwest, K4 Forum Mumbai Network
Revenue
$1M to $10M
People
Founders
Brigitte Apfel
Christian Apfel
About
SageMedic develops a genome-free SAGE Direct Platform that introduces the next generation of precision medicine by directly testing effective cancer treatments on a live tissue biopsy of a patient.
Products
Product
SageMedic develops a genome-free SAGE Direct Platform that introduces the next generation of precision medicine by directly testing effective cancer treatments on a live tissue biopsy of a patient.
Something missing or incorrect on this page? Help us enrich this information
